The FDA is dishing on the data that prompted it to halt enrollment for a multiple myeloma trial of a combination containing Venclexta.

No evidence of suspicious payments to Greek officials have been found, according to Novartis' own investigation and a report by a Greek expert panel.

Biogen investors' worst fears have come true: It's giving up on Alzheimer's prospect aducanumab. Is it “buy or be bought” time for the Big…

Jazz's Sunosi scored FDA approval to help narcolepsy and sleep apnea patients stay awake, but can't launch until it clears a final hurdle at DEA.

With a deal for the digoxin portfolio of Poland's Nobilus, C2 Pharma will have two supplies of API for making the sometimes difficult-to-get drug.…

A North Carolina federal jury found that Puma maliciously defamed Eshelman amid a proxy fight that began in late 2015.

Novo turned in its FDA application on Wednesday for oral semaglutide, which analysts believe will eventually pull in billions of dollars annually.

Merck KGaA says it will invest €1 billion in its headquarters site in Darmstadt, Germany, as part of a five-year agreement reached with workers there.